 Relmada Therapeutics Inc NASDAQ: RLMD has announced topline results of the human abuse potential HAP study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor NMDAR channel blocker and the Companys lead candidate. 